GENZYME CORPORATION

Genzyme Corporation specializes in the manufacturing of specialized pharmaceutical preparations, with deep expertise in the production of complex oral therapeutics for rare and chronic hematologic conditions. Their core capabilities include the formulation, quality control, and supply chain management of high-purity active pharmaceutical ingredients and finished dosage forms, particularly for niche oncology and immunology indications. The company demonstrates advanced proficiency in GMP-compliant manufacturing processes, batch traceability, and regulatory documentation for FDA-regulated biologics and small-molecule drugs, with demonstrated experience supporting VA-specific procurement requirements for branded specialty medications such as eliglustat (Cerdelga), caprelsa, and lemtrada. Their technical differentiation lies in the end-to-end delivery of temperature-sensitive, low-volume, high-complexity oral capsules meeting stringent federal pharmacopeial standards. Genzyme maintains a consistent and focused relationship with the Department of Veterans Affairs, providing mission-critical pharmaceuticals through blanket purchase agreements and Federal Supply Schedule contracts. Their work for the VA centers on sustaining reliable access to specialty therapeutics for veteran populations with rare diseases, including Gaucher disease and multiple sclerosis, ensuring continuity of care through dedicated supply chain protocols and regulatory alignment with VA formulary systems. The company’s primary industry focus is NAICS 325412—pharmaceutical preparation manufacturing—where they operate as a niche supplier of branded, patient-specific oral medications requiring stringent stability, bioavailability, and packaging controls. They serve the federal specialty pharmaceutical market with a vertical emphasis on hematologic and immunomodulatory therapies, positioning themselves as a trusted manufacturer for government agencies requiring assured supply of high-complexity, low-volume drugs. Genzyme Corporation is structured as a 2L entity headquartered in Cambridge, Massachusetts, with no publicly disclosed government certifications. Their geographic presence is centered in the biopharmaceutical corridor of eastern Massachusetts, leveraging proximity to research institutions and regulatory bodies to support federal procurement needs.